Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19

Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review

(2020) Ran Cheng et al.   International Journal of Oral Science

Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series

(2020) Achille Aouba et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19

(2020) Haralampos M Moutsopoulos   ANNALS OF THE RHEUMATIC DISEASES

IL‐1 blockade with anakinra in acute leukaemia patients with severe COVID‐19 pneumonia appears safe and may result in clinical improvement

(2020) James W. Day et al.   BRITISH JOURNAL OF HAEMATOLOGY

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis

(2020) George Dimopoulos et al.   Cell Host & Microbe

Use of anakinra in severe COVID-19: a case report

(2020) Giovanni Filocamo et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe Coronavirus disease 2019: A case report

(2020) Marco Franzetti et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease

(2020) Emanuele Pontali et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The COVID-19 pandemic

(2020) Marco Ciotti et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

The cytokine storm of COVID-19: a spotlight on prevention and protection

(2020) Lucie Pearce et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Cytokine Storms: Understanding COVID-19

(2020) Nilam Mangalmurti et al.   IMMUNITY

Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment

(2020) Andrés González-García et al.   RHEUMATOLOGY

Efficacy and Safety of Canakinumab in sJIA Patients with and without Fever at Baseline: Results from an Open‐label, Active Treatment Extension Study

(2020) Hermine I Brunner et al.   Arthritis & Rheumatology

Immunomodulatory Drugs in the Management of SARS-CoV-2

(2020) Daniel R. Burrage et al.   Frontiers in Immunology

Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)

(2020) Calvin C Sheng et al.   CLINICAL CARDIOLOGY

Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome

(2020) Massimo Caracciolo et al.   Frontiers in Immunology

Canakinumab provides rapid and sustained long‐term efficacy and safety in patients with cryopyrin‐associated periodic syndrome aged ≤5 years

(2019) Paul A Brogan et al.   Arthritis & Rheumatology

Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases

(2018) Giacomo Emmi et al.   Current Cardiology Reports

Dosage Considerations for Canakinumab in Children with Periodic Fever Syndromes

(2018) Luning Zhuang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases

(2017) Gabriele Fenini et al.   Frontiers in Pharmacology

The Effect of Rilonacept versus Placebo on Health-Related Quality of Life in Patients with Poorly Controlled Familial Mediterranean Fever

(2014) Philip J. Hashkes et al.   Biomed Research International

Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis

(2014) Norman T. Ilowite et al.   Arthritis & Rheumatology

Treating inflammation by blocking interleukin-1 in humans

(2013) Charles A. Dinarello et al.   SEMINARS IN IMMUNOLOGY

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

(2011) Paul M Ridker et al.   AMERICAN HEART JOURNAL

Inflammasome activation and IL-1β and IL-18 processing during infection

(2011) Frank L. van de Veerdonk et al.   TRENDS IN IMMUNOLOGY

Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies

(2008) Hal M. Hoffman et al.   ARTHRITIS AND RHEUMATISM